Logo Internet-AI colonne_top.png, 439B

Members



content_top.png, 479B

> Top story > PRESS RELEASES

PRESS RELEASES

This section presents our latest press releases.

 

PARTNERSHIP BETWEEN CHEM-X-INFINITY AND OXELTIS 02/01/2012

CHEM-X-INFINITY partnered with OXELTIS to design and produce focused libraries based on nucleosides. The compounds involve combinations of new sugars and bases and will have applications in the antiviral field and for some GPCRs.

PARTNERSHIP BETWEEN CHEM-X-INFINITY AND XANCHEM 27/09/2011

CHEM-X-INFINITY partnered with XANCHEM to produce libraries around original scaffolds. The compounds will be of particular interest in the oncology field.

PARTNERSHIP BETWEEN CHEM-X-INFINITY AND ORIBASE PHARMA 20/07/2011

CHEM-X-INFINITY partnered with ORIBASE PHARMA to offer kinase focused libraries. The compounds are built around several small aza-heterocycles underused in combinatorial libraries and will have applications in the oncology field.

CHEM-X-INFINITY WILL ATTEND THE 18TH MOLECULAR MEDICINE TRI-CONFERENCE 11/01/2011

CHEM-X-INFINITY will attend the 18th Molecular Medicine Tri-Conference on February 23rd-25th, 2011 in San Francisco, CA.

REPORT OF THE SCT ANNUAL WORKSHOP IN MEDICINAL CHEMISTRY 10/12/2010

The SCT Annual Workshop in Medicinal Chemistry was held the 7th of December in Paris at the Faculté de Médecine Cochin Port-Royal in collaboration with GFPP. Please read in this news our feeling about the event.

PARTNERSHIP BETWEEN CHEM-X-INFINITY AND DIVERCHIM 19/11/2010

CHEM-X-INFINITY partnered with DIVERCHIM to design and produce original libraries from synthetic analogues of natural compounds. The compounds will be of particular interest in the oncology field.

CHEM-X-INFINITY ATTENDED THE XXIst INTERNATIONAL SYMPOSIUM OF MEDICINAL CHEMISTRY 22/09/2010

CHEM-X-INFINITY attended the 21st International Symposium of Medicinal Chemistry on September 5th-9th, 2010, in Brussels, Belgium. Please read in this news our feeling about the event.

PARTNERSHIP BETWEEN CHEM-X-INFINITY AND I-STEM INSTITUTE (April 2010) 03/09/2010

CHEM-X-INFINITY partnered with I-Stem Institute to identify new treatments for monogenic diseases. Chem-X-Infinity will supply compound libraries, library focusing and early hit-optimization.

CHEM-X-INFINITY RECEIVED THE FRENCH RESEARCH TAX CREDIT ACCREDITATION 07/12/2009

CHEM-X-INFINITY is pleased to announce that it has received the accreditation for the French R&D tax credit for years 2009 to 2012. The system allows French companies to have a tax credit for R&D services outsourced in approved companies.

CHEM-X-INFINITY ATTENDED THE 5TH DRUG DESIGN AND LEAD DISCOVERY SUMMIT 01/10/2009

CHEM-X-INFINITY attended the 5th Drug Design and Lead Discovery Summit on October 14-16th, 2009, in San Diego, CA. The event covered new and common challenges faced during the research phase of the drug discovery process, as well as exciting and pertinent success stories. The conference had a focus on ligand-based drug design strategies that highlight the alternates, value, applicability, efficacy and effectiveness of pharmacophore-based strategies for lead finding and optimization.

footer_top.png, 537B